These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 9094984)

  • 1. Anatomic dissociation between HIV-1 and its endogenous inhibitor in mucosal tissues.
    Wahl SM; Worley P; Jin W; McNeely TB; Eisenberg S; Fasching C; Orenstein JM; Janoff EN
    Am J Pathol; 1997 Apr; 150(4):1275-84. PubMed ID: 9094984
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Endogenous mucosal antiviral factors of the oral cavity.
    Shugars DC
    J Infect Dis; 1999 May; 179 Suppl 3():S431-5. PubMed ID: 10099113
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endogenous salivary inhibitors of human immunodeficiency virus.
    Shugars DC; Alexander AL; Fu K; Freel SA
    Arch Oral Biol; 1999 Jun; 44(6):445-53. PubMed ID: 10401522
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibitory function of secretory leukocyte proteinase inhibitor (SLPI) in human saliva is HIV-1 specific and varies with virus tropism.
    Skott P; Lucht E; Ehnlund M; Björling E
    Oral Dis; 2002 May; 8(3):160-7. PubMed ID: 12108760
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Secretory leukocyte protease inhibitor (SLPI) in mucosal fluids inhibits HIV-I.
    Wahl SM; McNeely TB; Janoff EN; Shugars D; Worley P; Tucker C; Orenstein JM
    Oral Dis; 1997 May; 3 Suppl 1():S64-9. PubMed ID: 9456660
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Salivary secretory leukocyte protease inhibitor increases in HIV infection.
    Lin AL; Johnson DA; Stephan KT; Yeh CK
    J Oral Pathol Med; 2004 Aug; 33(7):410-6. PubMed ID: 15250833
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of the oral environment in HIV-1 transmission.
    Shugars DC; Wahl SM
    J Am Dent Assoc; 1998 Jul; 129(7):851-8. PubMed ID: 9685760
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human immunodeficiency virus type 1 stimulates the expression and production of secretory leukocyte protease inhibitor (SLPI) in oral epithelial cells: a role for SLPI in innate mucosal immunity.
    Jana NK; Gray LR; Shugars DC
    J Virol; 2005 May; 79(10):6432-40. PubMed ID: 15858026
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Secretory leukocyte protease inhibitor: a human saliva protein exhibiting anti-human immunodeficiency virus 1 activity in vitro.
    McNeely TB; Dealy M; Dripps DJ; Orenstein JM; Eisenberg SP; Wahl SM
    J Clin Invest; 1995 Jul; 96(1):456-64. PubMed ID: 7615818
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral transmission of HIV, reality or fiction? An update.
    Campo J; Perea MA; del Romero J; Cano J; Hernando V; Bascones A
    Oral Dis; 2006 May; 12(3):219-28. PubMed ID: 16700731
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhanced secretory leukocyte protease inhibitor in human immunodeficiency virus type 1-infected patients.
    Baqui AA; Meiller TF; Falkler WA
    Clin Diagn Lab Immunol; 1999 Nov; 6(6):808-11. PubMed ID: 10548568
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Salivary concentration of secretory leukocyte protease inhibitor, an antimicrobial protein, is decreased with advanced age.
    Shugars DC; Watkins CA; Cowen HJ
    Gerontology; 2001; 47(5):246-53. PubMed ID: 11490143
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of oral secretory leukocyte protease inhibitor in HIV-infected subjects with long-term use of antiretroviral therapy.
    Nittayananta W; Kemapunmanus M; Yangngam S; Talungchit S; Sriplung H
    J Oral Pathol Med; 2013 Mar; 42(3):208-15. PubMed ID: 23126266
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Salivary secretory leukocyte protease inhibitor is associated with reduced transmission of human immunodeficiency virus type 1 through breast milk.
    Farquhar C; VanCott TC; Mbori-Ngacha DA; Horani L; Bosire RK; Kreiss JK; Richardson BA; John-Stewart GC
    J Infect Dis; 2002 Oct; 186(8):1173-6. PubMed ID: 12355371
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Salivary secretory leukocyte protease inhibitor and oral candidiasis in human immunodeficiency virus type 1-infected persons.
    Chattopadhyay A; Gray LR; Patton LL; Caplan DJ; Slade GD; Tien HC; Shugars DC
    Infect Immun; 2004 Apr; 72(4):1956-63. PubMed ID: 15039315
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Secretory leukocyte protease inhibitor and its potential interactions with elastase and cathepsin B in gingival crevicular fluid and saliva from patients with chronic periodontitis.
    Cox SW; Rodriguez-Gonzalez EM; Booth V; Eley BM
    J Periodontal Res; 2006 Oct; 41(5):477-85. PubMed ID: 16953825
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Secretory leukocyte protease inhibitor blocks infectivity of primary monocytes and mononuclear cells with both monocytotropic and lymphocytotropic strains of human immunodeficiency virus type I.
    Shugars DC; Sauls DL; Weinberg JB
    Oral Dis; 1997 May; 3 Suppl 1():S70-2. PubMed ID: 9456661
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of human immunodeficiency virus type 1 infectivity by secretory leukocyte protease inhibitor occurs prior to viral reverse transcription.
    McNeely TB; Shugars DC; Rosendahl M; Tucker C; Eisenberg SP; Wahl SM
    Blood; 1997 Aug; 90(3):1141-9. PubMed ID: 9242546
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential mucosal susceptibility in HIV-1 transmission and infection.
    Moutsopoulos NM; Greenwell-Wild T; Wahl SM
    Adv Dent Res; 2006 Apr; 19(1):52-6. PubMed ID: 16672550
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Secretory leukocyte protease inhibitor (SLPI): oxidation of SLPI does not explain its variable anti-HIV activity.
    Konopka K; Shine N; Pretzer E; Düzgüneş N
    J Dent Res; 1999 Dec; 78(12):1773-6. PubMed ID: 10598905
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.